Pulmatrix, Inc. announced publication of "Evaluation of the Potential for Drug-Drug Interactions with Inhaled Itraconazole Using Physiologically Based Pharmacokinetic Modelling, Based on Phase 1 Clinical Data" in the peer-reviewed American Association of Pharmaceutical Scientists (AAPS) Journal. This study demonstrates the risk of DDI with PUR1900 (inhaled itraconazole) is lower than with oral itraconazole and PUR1900 may be safely administered even in patients taking drugs contraindicated with oral itraconaz Hole therapy. While oral itraconazole is part of the standard of care for patients suffering from ABPA, its use is limited due to the side effects and drug to drug interactions associated with the high itraconazole plasma concentrations of oral itraconazole therapy.

The premier journals of the American Association of Pharmaceutical Scientists have established a position of leadership among pharmaceutical scientists and successfully disseminate expert, high-quality content to the pharmaceutical sciences community.